Tessera Therapeutics
Focus: Tessera Therapeutics is a gene-writing biotech focused on in vivo gene editing for rare diseases, based in Somerville, MA. The company operates at pre-revenue stage with early-stage clinical programs.
Profile data last refreshed 11h ago · AI intelligence enriched 2mo ago
Open Jobs
7
5 recent layoff filings (12 mo) — 168 affected
- 1/12/2026 — Unknown/Unknown, OH · 1 affected · Layoff
- 1/7/2026 — Somerville, MA · 82 affected · Layoff
- 1/7/2026 — Remote, CT · 1 affected · Layoff
- +2 more
Source: state DOL filings via Big Local News
Should You Work at Tessera Therapeutics?
AI assessmentA high-risk, high-upside early-stage play best suited to risk-tolerant candidates who value platform exposure and rare-disease focus over stability.
Why Work Here
- Ground-floor opportunity in gene writing, a differentiated modality with fewer competitors than traditional gene therapy
- Lead program TSRA-196 received FDA Fast Track and Orphan Drug designations (Feb 2026), signaling regulatory confidence
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_1_2
Clinical Trials (1)
NCT07227207A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)
Phase 1/2Help build intelligence for Tessera Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.